We are thrilled to announce that Egle Pavyde has joined APICES CRO as Vice President of Business Development. With over 10 years of experience in the clinical trials field, she brings the expertise needed to help APICES’ clients achieve their research objectives across Europe and global markets.
With a background in pharmacy and a PhD in Life Sciences, Egle combines deep scientific knowledge with strong leadership and strategic insight. Throughout her career, she has successfully driven business growth, cultivated collaborations with pharmaceutical and biotech teams, and helped clients progress and achieve their clinical trial goals.
In her new role at APICES, she will focus on enhancing client engagement, expanding our service offerings, and guiding clients to accelerate their research programs. Her work will empower our clients to progress their studies effectively, ultimately contributing to the development of therapies that improve patient’s health and outcomes.
We are confident that Egle’s arrival will play a key role in strengthening APICES’ client partnerships and driving our growth, while helping clients achieve their research goals. We look forward to collaborating with our clients and partners to deliver high-quality clinical solutions and make a real difference in patients’ lives.
“We are confident that the addition of Egle Pavyde will provide a significant boost in consolidating APICES’ position in the market and strengthening our strategic partnerships. Her experience and leadership will be key to supporting our clients in the development of high-quality clinical research projects,” stated Óscar Salamanca, CEO of APICES.
Interested in achieving your clinical research objectives? Contact APICES and discover how enables progress in clinical studies and improves patient outcomes.
You can find further information in the following link: pmfarma.com/app/noticias/60048-egle-pavyde-se-incorpora-a-apices-como-vicepresidenta-de-business-development
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
